NASDAQ:CRNX Crinetics Pharmaceuticals (CRNX) Stock Price, News & Analysis $30.10 +0.60 (+2.05%) As of 03:49 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Crinetics Pharmaceuticals Stock (NASDAQ:CRNX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CRNX alerts:Sign Up Key Stats Today's Range$29.30▼$30.6450-Day Range$25.56▼$35.9452-Week Range$24.10▼$62.53Volume627,107 shsAverage Volume1.01 million shsMarket Capitalization$2.82 billionP/E RatioN/ADividend YieldN/APrice Target$74.56Consensus RatingModerate Buy Company OverviewCrinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.Read More… Crinetics Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks76th Percentile Overall ScoreCRNX MarketRank™: Crinetics Pharmaceuticals scored higher than 76% of companies evaluated by MarketBeat, and ranked 239th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingModerate Buy Consensus RatingCrinetics Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.91, and is based on 10 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageCrinetics Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Crinetics Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Crinetics Pharmaceuticals are expected to decrease in the coming year, from ($3.73) to ($4.11) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Crinetics Pharmaceuticals is -8.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Crinetics Pharmaceuticals is -8.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCrinetics Pharmaceuticals has a P/B Ratio of 3.71. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Crinetics Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.51% of the outstanding shares of Crinetics Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverCrinetics Pharmaceuticals has a short interest ratio ("days to cover") of 9.7.Change versus previous monthShort interest in Crinetics Pharmaceuticals has recently increased by 2.18%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCrinetics Pharmaceuticals does not currently pay a dividend.Dividend GrowthCrinetics Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG3.7 / 5Environmental Score-0.62 Percentage of Shares Shorted10.51% of the outstanding shares of Crinetics Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverCrinetics Pharmaceuticals has a short interest ratio ("days to cover") of 9.7.Change versus previous monthShort interest in Crinetics Pharmaceuticals has recently increased by 2.18%, indicating that investor sentiment is decreasing. News and Social Media4.1 / 5News Sentiment1.43 News SentimentCrinetics Pharmaceuticals has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.03 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Crinetics Pharmaceuticals this week, compared to 7 articles on an average week.Search Interest2 people have searched for CRNX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows3 people have added Crinetics Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Crinetics Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $923,913.00 in company stock.Percentage Held by InsidersOnly 4.60% of the stock of Crinetics Pharmaceuticals is held by insiders.Percentage Held by Institutions98.51% of the stock of Crinetics Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Crinetics Pharmaceuticals' insider trading history. Receive CRNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Crinetics Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address CRNX Stock News HeadlinesCrinetics Pharmaceuticals’ SWOT analysis: oral endocrine drug stock poised for growthMay 23, 2025 | investing.comCrinetics Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2025May 23, 2025 | globenewswire.comElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless production of electric vehicles and solar technology is driving demand for the precious metal to unprecedented levels. Silver—critical for EV batteries, solar panels, and advanced electronics—is now at the center of a supply crisis.May 28, 2025 | GoldenCrest Metals (Ad)Crinetics to Present New Research on Paltusotine, Atumelnant and Unmet Needs in Acromegaly Treatment at the American Association of Clinical Endocrinology Annual Meeting 2025May 15, 2025 | globenewswire.comCrinetics Pharmaceuticals Announces May 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 12, 2025 | finance.yahoo.comCrinetics Pharmaceuticals Announces May 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 12, 2025 | globenewswire.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q1 2025 Earnings Call TranscriptMay 10, 2025 | msn.comCrinetics Pharmaceuticals, Inc (CRNX) Q1 2025 Earnings Call TranscriptMay 10, 2025 | seekingalpha.comSee More Headlines CRNX Stock Analysis - Frequently Asked Questions How have CRNX shares performed this year? Crinetics Pharmaceuticals' stock was trading at $51.13 at the start of the year. Since then, CRNX stock has decreased by 41.4% and is now trading at $29.9550. View the best growth stocks for 2025 here. How were Crinetics Pharmaceuticals' earnings last quarter? Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) posted its quarterly earnings results on Thursday, May, 8th. The company reported ($1.04) EPS for the quarter, missing analysts' consensus estimates of ($0.99) by $0.05. The business's revenue for the quarter was down 43.6% compared to the same quarter last year. Read the conference call transcript. When did Crinetics Pharmaceuticals IPO? Crinetics Pharmaceuticals (CRNX) raised $80 million in an initial public offering (IPO) on Wednesday, July 18th 2018. The company issued 5,000,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Leerink Partners and Piper Jaffray acted as the underwriters for the IPO. Who are Crinetics Pharmaceuticals' major shareholders? Top institutional shareholders of Crinetics Pharmaceuticals include Vanguard Group Inc. (9.95%), Wellington Management Group LLP (7.36%), Driehaus Capital Management LLC (6.66%) and Price T Rowe Associates Inc. MD (5.46%). Insiders that own company stock include Richard Scott Struthers, Marc Wilson, Jeff E Knight, Dana Pizzuti, Stephen F Betz, Alan Seth Krasner, James Hassard, Matthew K Fust, Stephanie Okey and Coelho Rogerio Vivaldi. View institutional ownership trends. How do I buy shares of Crinetics Pharmaceuticals? Shares of CRNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Crinetics Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Crinetics Pharmaceuticals investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), ServiceNow (NOW) and Advanced Micro Devices (AMD). Company Calendar Last Earnings5/08/2025Today5/28/2025Next Earnings (Estimated)8/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CRNX CIK1658247 Webwww.crinetics.com Phone(858) 450-6464FaxN/AEmployees210Year FoundedN/APrice Target and Rating Average Stock Price Target$74.56 High Stock Price Target$97.00 Low Stock Price Target$54.00 Potential Upside/Downside+152.7%Consensus RatingModerate Buy Rating Score (0-4)2.91 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($3.82) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$214.53 million Net MarginsN/A Pretax Margin-26,298.27% Return on Equity-36.12% Return on Assets-31.89% Debt Debt-to-Equity RatioN/A Current Ratio16.39 Quick Ratio16.38 Sales & Book Value Annual Sales$760,000.00 Price / Sales3,634.28 Cash FlowN/A Price / Cash FlowN/A Book Value$8.07 per share Price / Book3.66Miscellaneous Outstanding Shares93,629,000Free Float87,174,000Market Cap$2.76 billion OptionableOptionable Beta0.31 The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:CRNX) was last updated on 5/28/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | Sponsored“You all just got a lot richer”Trump Knows What He’s Doing. When the president says he’s going to let RFK “go wild” … and Big Pharma crash...Brownstone Research | SponsoredUrgent: Make this trade before you hit your pillow tonight… Most people waste 8 hours every night… And 227,916 hours in their lifetime… Dreaming about the life they...Timothy Sykes | SponsoredThe biggest threat isn’t ChinaWhile the headlines focus on AI models and chip speed, Elon Musk is investing in the material side of the stor...True Market Insiders | SponsoredBig Oil’s big pivotThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Crinetics Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Crinetics Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.